Oncolytic Virus Engineering
The platform in the Creative Biolabs provides a one-stop solution of oncolytic virus engineering. Our brilliant scientists can manipulate the oncolytic virus to meet the needs for your research, preclinical study and drug development. The oncolytic viruses can be manipulated to alter the capsid to reduce pathogenicity and immunogenicity, to secret antibody to boost the anti-tumor immune response, to express cytokine/chemokine to attract immune cells migration to the tumor site, and even to be loaded with immune checkpoint inhibitors.
Oncolytic viruses are a group of virus that specifically lyze tumor cells but not health cell in humans. Pathogenic elements of oncolytic virus must be mutated or deleted before being used for tumor therapy.
The anti-tumor effect of oncolytic virus is often limited by the immunogenicity of virus which may induce neutralization antibody to inactivate the virus and decrease viral load in patients. However, the oncolytic viruses can be manipulated to alter the capsid to reduce immunogenicity, to secret antibody to boost the anti-tumor immune response, to express cytokine/chemokine to attract immune cells migration to the tumor site, and even to be loaded with immune checkpoint inhibitors. Scientists in Creative Biolabs have developed new strategy to reduce immunogenicity of oncolytic virus to prevent clearance from the patients’ immune system.
Antibody is an effective cancer therapy. Antibody is usually delivered to the patients by systemic administration, which may induce systemic toxicity and limit the antibody level in tumor environment. Scientists in CREATIVE BIOLABS have developed a strategy to manipulate the oncolytic virus expressing customized antibody in order to reduce toxicity and increase efficacy.
Cytokine/chemokine is a group of proteins secreted by host cells to boost or relocate immune cells to local tumor environment and increase anti-tumor immune response. Scientists in Creative Biolabs have developed a strategy to manipulate the oncolytic virus expressing customized cytokine/chemokine to boost the anti-tumor immune response.
Immune checkpoint inhibitors are a new class of small molecules that has been proved by FDA to be used in patients. This group of molecules includes antibodies of PD1, PD-L1, CXCL4 and extra-cellular domain of PD1, PD-L1 and CXCL4 protein. Scientists in Creative Biolabs have developed a strategy to manipulate the oncolytic virus to deliver the immune checkpoint inhibitors to the tumor environment to reduce toxicity and increase efficacy.
Please feel free to contact us for a quote and further discussion with our scientists.
